Works matching AU Huang, Dingzhi

Results: 47
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15

    A multicenter, randomized, double-blind, placebo-controlled phase 3 study of Socazolimab or placebo combined with carboplatin and etoposide in the first-line treatment of extensive-stage small cell lung cancer.

    Published in:
    Signal Transduction & Targeted Therapy, 2025, v. 10, n. 1, p. 1, doi. 10.1038/s41392-024-02115-5
    By:
    • Chen, Zhiwei;
    • Chen, Jianhua;
    • Huang, Dingzhi;
    • Zhang, Wei;
    • Wu, Lin;
    • Yi, Tienan;
    • Wang, Qiming;
    • Han, Liang;
    • Tan, Liping;
    • Li, Yinyin;
    • Zhang, Zhihong;
    • Li, Na;
    • li, Jie;
    • Zhang, Tongmei;
    • Hu, Ying;
    • Sun, Hongmei;
    • Wu, Youhua;
    • He, Zhiyong;
    • Yang, Runxiang;
    • Cheng, Peng
    Publication type:
    Article
    16
    17
    18

    Patient-reported outcomes following selpercatinib treatment in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer and thyroid cancer, and RET -mutant medullary thyroid cancer in the phase II LIBRETTO-321 trial.

    Published in:
    Therapeutic Advances in Medical Oncology, 2023, v. 15, p. 1, doi. 10.1177/17588359231189429
    By:
    • Lu, Shun;
    • Zheng, Xiangqian;
    • Sun, Yuping;
    • Huang, Dingzhi;
    • Wu, Lin;
    • Ji, Qinghai;
    • Zhou, Chengzhi;
    • Zhou, Jianying;
    • Guo, Ye;
    • Ge, Minghua;
    • Ding, Ding;
    • Shao, Jingxin;
    • Zhang, Wanli;
    • Gao, Ming;
    • Cheng, Ying
    Publication type:
    Article
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39

    Rechallenge of immune checkpoint inhibitors in advanced non‐small cell lung cancer.

    Published in:
    Thoracic Cancer, 2024, v. 15, n. 5, p. 419, doi. 10.1111/1759-7714.15209
    By:
    • Lin, Gen;
    • Wang, Zhijie;
    • Chu, Qian;
    • Hu, Yi;
    • Huang, Dingzhi;
    • Wang, Jun;
    • Yang, Fan;
    • Zhong, Wenzhao;
    • Zhou, Chengzhi;
    • Zhu, Bo;
    • Ai, Xinghao;
    • Cao, Baoshan;
    • Cao, Yabing;
    • Chen, Mingqiu;
    • Chen, Xiaohui;
    • Chu, Tianqing;
    • Duan, Jianchun;
    • Fan, Yun;
    • Fang, Yong;
    • Feng, Shuitu
    Publication type:
    Article
    40
    41
    42
    43

    Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study.

    Published in:
    Molecular Cancer, 2023, v. 22, n. 1, p. 1, doi. 10.1186/s12943-023-01823-w
    By:
    • Zhang, Linlin;
    • Wang, Liuchun;
    • Wang, Jingya;
    • Chen, Jinliang;
    • Meng, Zhaoting;
    • Liu, Zhujun;
    • Jiang, Xiangli;
    • Wang, Xinyue;
    • Huang, Chun;
    • Chen, Peng;
    • Liang, Yan;
    • Jiang, Richeng;
    • Wang, Jing;
    • Zhong, Diansheng;
    • Shang, Yanhong;
    • Zhang, Yan;
    • Zhang, Cuiying;
    • Huang, Dingzhi
    Publication type:
    Article
    44
    45
    46
    47